Collaboration Goals Sample Clauses

Collaboration Goals. The Collaboration has the following goals: • To support and advance the mission of each Party through exchange and transfer of knowledge and expertise; • To be thought leaders, creating intellectual capital that shapes and influences debate and leads to actions that advance identity management, data privacy, and security innovation; • To improve public and private sector trust and ability to adopt innovations in the United States, Canada, and globally through the development of research projects, pilots, and proofs of concept.
Sample 1Sample 2See All (7)
AutoNDA by SimpleDocs
Collaboration Goals. Pursuant and subject to the terms of this Agreement, within the Field and the Territory, the Parties agree to: (a) engage in Development activities with the goal of obtaining Regulatory Approval for Antegren or, as applicable, other Licensed Product, as soon as reasonably practicable, in one or more Commercially Significant Indications in each Major Market Country where it makes commercial sense to do so given the size of the potential market and the safety and efficacy profile of Licensed Product and (b) engage in Commercialization of Antegren, or, as applicable, other Licensed Product, with the goal of optimizing the profit available to each Party. For purposes of clarity, it is understood by the Parties that the JCT may decide that it does not make commercial sense for the Parties to Develop or Commercialize Licensed Product in a particular Major Market Country in a given indication. Each Party agrees to use Commercially Reasonable and Diligent Efforts in performing its tasks and responsibilities and in conducting all activities ascribed or assigned to it under this Agreement, the then current Development Plan, any Annual Work Plan/Budget, the then current Commercialization Plan and any Annual Commercialization Plan/Budget. Each Party shall cooperate with and provide reasonable support to the other Party in performing its activities with respect to the Development and Commercialization work contemplated hereunder. Each Party agrees, during the Term, to Develop, manufacture, Commercialize and Promote Licensed Products only under the terms of this Agreement. The Parties' intent is to Develop, Commercialize, manufacture and Promote Antegren or, as applicable, other Licensed Product, as expeditiously as reasonably practicable with the resources and responsibilities allocated between the Parties on the basis of each Party's respective capabilities and availability of adequate capacities, either internally or through such subcontractors as are customarily used by a Party. Unless otherwise specified in this Agreement, the guiding principles to be followed by the JSC, the Joint Project Team and the JCT are as follows: achieve synergy and avoid duplication of resources; maximize the profitability of Antegren or, as applicable, other Licensed Product, over its life; and utilize, to the extent practicable, the then-prevailing infrastructure and expertise of each Party with respect to specific Development activities and any specific indication and utilize, on a cou...
Sample 1Sample 2
Collaboration Goals. Pursuant and subject to the terms of this Agreement and the TTA, the Parties agree: (a) that NovaMedica (i) engages in Development activities with the goal of obtaining Regulatory Approval for any of the Covered Products, as soon as reasonably practicable, in the Territory and (ii) thereafter conducts the Commercialization of the Covered Products in the Territory, and (b) that Company (i) through its membership on the JSC, JDC and JCC, participates in the planning and oversight of such Development and Commercialization activities and (ii) provides such other assistance as is set forth in this Agreement and the TTA. Notwithstanding anything in this Agreement to the contrary, either Party shall be free to work alone or with Third Parties to research, develop, manufacture and/or commercialize any product that is not a Covered Product in or outside the Field.
Sample 1Sample 2
Collaboration Goals. Pursuant and subject to the terms of this Agreement, within the Field and the Territory, the Parties agree to collaborate in the Development and Commercialization of Covered Product each supporting the Joint Steering, Development and Commercialization Team activities as outlined in Section 3. All other advice and assistance shall be mutually agreed by the Parties. NovaMedica shall promptly reimburse Marinus for all Out-of-Pocket Expenses incurred by Marinus in performing its obligations under this Agreement according to its terms. Notwithstanding anything in this Agreement to the contrary, NovaMedica shall be free to work alone or with Third Parties to research, develop, manufacture and/or commercialize any product that is not a Covered Product in or outside the Field in the Territory in accordance with the TTA, and Marinus shall be free to work alone or with Third Parties to research, develop, manufacture and/or commercialize any Covered Product outside the Territory and any and all products that are not a Covered Product anywhere in the world. Consistent with the TTA, Marinus shall have no obligation to perform any clinical trials in the Territory, except to the extent expressly agreed in writing by the Parties.
Sample 1
Collaboration Goals. The Parties agree, pursuant and subject to the terms of this Agreement, to develop Licensed Products, with the goal of obtaining Regulatory Approval of Licensed Products in commercially significant indications as soon as reasonably practicable for commercial marketing and sale in the Field in the Territory, pursuant to this Agreement. Each Party shall use Commercially Reasonable and Diligent Efforts to perform its respective tasks and obligations in conducting all development work ascribed to it in the Development Budget/Plan, and each Party shall cooperate with and provide reasonable support to the other Party in such other Party's conduct of such development and commercialization work as provided in the Development Budget/Plan.
Sample 1
Collaboration Goals. 19 2.2 Exclusive Working Relationship......................................19
Sample 1
Collaboration Goals. Pursuant and subject to the terms of this Agreement, the Parties agree to: (a) engage in discovery and Research activities with the goal of identifying one or more R&D Candidates in the Field, (b) engage in Development activities with the goal of obtaining Regulatory Approval for Collaboration Products in the Territory where it makes commercial sense to do so given the size of the potential market and the safety and efficacy profile of each Collaboration Product and (c) engage in Commercialization of Collaboration Products with the goal of optimizing the profit available to each Party. For purposes of clarity, it is understood by the Parties that the JSC may decide that it does not make commercial sense for the Parties to Develop or Commercialize a Collaboration Product in a particular country in the Territory. Each Party agrees to use Commercially Reasonable Efforts in performing its tasks and responsibilities and in conducting all activities ascribed or assigned to it under this Agreement, the then current Annual Research Plan, Annual Development Plan, any Annual Research Budget, Annual Development Budget, the then current Commercialization Plan and any Annual Commercialization Plan. Each Party shall cooperate with and provide reasonable support to the other Party in performing its activities with respect to the Research, Development and Commercialization work contemplated hereunder. Each Party agrees, during the term of this Agreement, to Develop, Manufacture, and Commercialize, as applicable, Collaboration Products, Party Exclusive Products and Non-Antibody Products, only under the terms of this Agreement.
Sample 1
AutoNDA by SimpleDocs
Collaboration Goals. (a) Pursuant and subject to the terms of this Agreement:
Sample 1
Collaboration Goals. Consistent with the TTA and subject to the terms and conditions set forth herein, Regado agrees to assist NovaMedica in the Development and Commercialization of Covered Products in the Territory. Notwithstanding anything in this Agreement to the contrary, either Party shall be free to work alone or with Third Parties to research, develop, manufacture and/or commercialize any product that is not a Covered Product in or outside the Field.
Sample 1

Related to Collaboration Goals

  • Research Plan The Parties recognize that the Research Plan describes the collaborative research and development activities they will undertake and that interim research goals set forth in the Research Plan are good faith guidelines. Should events occur that require modification of these goals, then by mutual agreement the Parties can modify them through an amendment, according to Paragraph 13.6.

  • Research Program 2.1 University will use reasonable efforts to conduct the Research Program described in Attachment A which is hereby incorporated in full by reference (“Research Program”), and will furnish the facilities necessary to carry out said Research Program. The Research Program will be under the direction of _____________________ (“Principal Investigator”), or his or her successor as mutually agreed to by the Parties and will be con­ducted by the Principal Investigator at the University.

  • Development Program A. Development activities to be undertaken (Please break activities into subunits with the date of completion of major milestones)

  • Collaboration We believe joint effort toward common goals achieves trust and produces greater impact for L.A. County’s youngest children and their families.

  • Research Program Term The Research Program shall be conducted during the period of five years commencing as of the Agreement Date ("Research Program Term"). Upon not later than seventy-five (75) days' prior written notice JT may, in its sole judgment, terminate the Research Program at the end of the third (3/rd/) year and fourth (4/th/) year of the Research Program. The RMC may terminate the Research Program any time during the Research Program Term if it unanimously determines the Research Program is no longer scientifically useful or that all potential Products would not be commercially viable. In case of such an early termination by JT or the RMC, JT shall be exempt from any payment(s) under Section 10(a) that would have become due and payable after the effective date of such early termination. Following any termination of the Research Program (i) that occurs simultaneously with the termination of this Agreement in accordance with Section 13 (i.e., no compound or Lead Compound has been designated previously a Collaboration Lead Compound in accordance with Section 3(b) and no Independent Lead Compound is being developed in accordance with Section 3(m)) or (ii) that is followed at some future date by the termination by JT of Development or co-promotion of any Collaboration Lead Compound and/or Product pursuant to Sections 3(l) or 5(c), respectively, or development of an Independent Lead Compound in accordance with Section 3(m) (A) any licenses granted by Tularik to JT will terminate, (B) JT will grant to Tularik an exclusive, sublicensable, worldwide license, to make, use and sell compounds, Collaboration Lead Compounds or Products under JT's interest in Program Patents and Program Know-How and (C) under the terms and conditions to be separately agreed, JT will also grant to Tularik a nonexclusive, sublicensable, worldwide license under any JT Patent Rights and Know-How to the extent necessary to practice the license granted under the Program Patents and Program Know-How in (B) (including, with respect to compounds, a limited number of JT's library compounds approved by JT); provided, however, that in the event the Research Program terminates but the Agreement has not terminated with respect to designated Collaboration Lead Compounds, Independent Lead Compounds and/or Products as provided in Section 2(g)(ii), Sections 2(g)(A), (B) and (C) shall apply only to those compounds, Collaboration Lead Compounds, Independent Lead Compounds and Products for which Development or co-promotion shall have been terminated and/or to those compounds or Lead Compounds that have not been designated previously a Collaboration Lead Compound in accordance with Section 3(b) or an Independent Lead Compound in accordance with Section 3(m); provided further that in the event that JT elects to pursue a Discontinued Compound or a Non-Proposed Compound on or before the first anniversary of the expiration or termination of the Research Program Term pursuant to Section 3(b)(iii) or 3(b)(iv), respectively, Sections 2(g)(A), (B) and (C) shall not apply to such Discontinued Compound or Non-Proposed Compound until such time as JT shall have terminated the Development or co-promotion of such Discontinued Compound or Non- Proposed Compound. Tularik will then be free to pursue clinical development and registration of such compounds, Lead Compounds and/or Products without obligation to JT except as provided in Section 4(f) or Section 5(c), as appropriate.

  • Research Plans The Research Plan for the [***] Designated Target is attached as Schedule 2.2.3-1. Subsequent Research Plans agreed upon in accordance with Section 2.4.2.4 will be attached as additional sequentially numbered schedules (Schedule 2.2.3-2, Schedule 2.2.3-3, etc.).

  • Commercialization Plan On a Product by Product basis, not later than sixty (60) days after the filing of the first application for Regulatory Approval of a Product in the Copromotion Territory, the MSC shall prepare and approve a rolling multiyear (not less than three (3) years) plan for Commercializing such Product in the Copromotion Territory (the "Copromotion Territory Commercialization Plan"), which plan includes a comprehensive market development, marketing, sales, supply and distribution strategy for such Product in the Copromotion Territory. The Copromotion Territory Commercialization Plan shall be updated by the MSC at least once each calendar year such that it addresses no less than the three (3) upcoming years. Not later than thirty (30) days after the filing of the first application for Regulatory Approval of a Product in the Copromotion Territory and thereafter on or before September 30 of each calendar year, the MSC shall prepare an annual commercialization plan and budget (the "Annual Commercialization Plan and Budget"), which plan is based on the then current Copromotion Territory Commercialization Plan and includes a comprehensive market development, marketing, sales, supply and distribution strategy, including an overall budget for anticipated marketing, promotion and sales efforts in the upcoming calendar year (the first such Annual Development Plan and Budget shall cover the remainder of the calendar year in which such Product is anticipated to be approved plus the first full calendar year thereafter). The Annual Commercialization Plan and Budget will specify which Target Markets and distribution channels each Party shall devote its respective Promotion efforts towards, the personnel and other resources to be devoted by each Party to such efforts, the number and positioning of Details to be performed by each Party, as well as market and sales forecasts and related operating expenses, for the Product in each country of the Copromotion Territory, and budgets for projected Pre-Marketing Expenses, Sales and Marketing Expenses and Post-Approval Research and Regulatory Expenses. In preparing and updating the Copromotion Territory Commercialization Plan and each Annual Commercialization Plan and Budget, the MSC will take into consideration factors such as market conditions, regulatory issues and competition.

  • Development Plan document specifying the work program, schedule, and relevant investments required for the Development and the Production of a Discovery or set of Discoveries of Oil and Gas in the Contract Area, including its abandonment.

  • Research Program Funding 3.1.1 Pfizer will fund the research to be performed by Rigel, pursuant to the Agreement, according to the following schedule: COMMITMENT YEAR ANNUAL COMMITMENT 1 $2,350,000.00 2 $2,350,000.00 The funding payments of two million three hundred and fifty thousand dollars ($2,350,000.00) shall support the work of the equivalent of ten (10) full time employees ("FTEs") of Rigel.

  • Research Collaboration Upon FibroGen’s request, the Parties will discuss conducting a research program funded by AstraZeneca and directed toward franchise enhancement and lifecycle management for HIF Compounds or other topics that the Parties determine relevant to the Products and the Field. Upon agreement on the terms of such research program, the Parties will enter into a separate agreement or amend this Agreement accordingly.

Time is Money Join Law Insider Premium to draft better contracts faster.